TLR2 and pneumococcal meningitis: Consequently, combining antimicrobial therapy with TLR2- and endosomal TLR–specific antagonists effectively protected mice from pneumococcal meningitis pathology and significantly inhibited S. pneumoniae–induced activation of murine macrophages and human PBMCs in which TLR8 substitutes for TLR13.